RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. Utilizing its proprietary discovery and development engine, the company develops highly selective small molecules that are designed to modulate the fundamental immune responses underlying these diseases. RAPT has rapidly discovered and advanced two unique drug candidates each targeting CCR4, including our lead oncology drug candidate, FLX475, now in clinical development and our lead inflammation drug candidate, RPT193, expected to enter the clinic in the second half of 2019. The company is also pursuing other discovery targets including GCN2 and HPK1 for the treatment of cancer.

Company Details

Website: https://rapt.com/

Size: 51-200 employees

Founded: 2015

Headquaters: san francisco, california, united states

Rapt Org Chart

Gene Cutler
Senior Director, Computa...
View Employees

Gene Cutler

Senior Director, Computational Biology

How Rapt makes Decision

Average Buying Committee Size


See Rapt Buying Process

Get Details